Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23879097 | 1.00 | HPGD (0.38) | HPGDCTSKITGB3ITGA2BCYP2D6 | |
| SCHEMBL26013230 | 0.87 | HPGD (0.38) | HPGDCTSKITGB3ITGA2BCYP2D6 | |
| SCHEMBL7298353 | 0.86 | CYP2D6 (0.46) | CTSKITGB3ITGA2BCYP2D6CTSL | |
| SCHEMBL23879161 | 0.86 | SMN1; SMN2 (0.49) | CTSKCTSLCTSBMEN1CYP3A4 | |
| SCHEMBL23893541 | 0.84 | P2RY12 (0.36) | HPGDCTSKITGB3ITGA2BCYP2D6 | |
| SCHEMBL26010069 | 0.84 | CTSK (0.41) | CTSKITGB3ITGA2BCYP2D6CTSL | |
| SCHEMBL14580885 | 0.83 | CTSK (0.38) | HPGDCTSKITGB3ITGA2BCYP2D6 | |
| SCHEMBL13030795 | 0.83 | CTSK (0.35) | HPGDCTSKITGB3ITGA2BCYP2D6 | |
| SCHEMBL22044175 | 0.79 | DPP4 (0.41) | HPGDCTSKCYP2D6MEN1KMT2A | |
| SCHEMBL15083289 | 0.78 | MMP1 (0.39) | HPGDMMP1MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-14 | — | — | US | disclosed |
| US-12312379-B2 | Methods for producing cyclic compounds comprising N-substituted amino acid residues | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-27 | — | — | US | disclosed |
| US-20240024245-A1 | MEDICINE PRODUCTION METHOD INCLUDING STEP OF FREEZE-DRYING WITH MIXED SOLVENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240024245-A1 | MEDICINE PRODUCTION METHOD INCLUDING STEP OF FREEZE-DRYING WITH MIXED SOLVENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240024245-A1 | MEDICINE PRODUCTION METHOD INCLUDING STEP OF FREEZE-DRYING WITH MIXED SOLVENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-4248951-A1 | MEDICINE PRODUCTION METHOD INCLUDING STEP OF FREEZE-DRYING WITH MIXED SOLVENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-27 | — | — | EP | disclosed |
| US-20220411462-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20220411462-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-12-29 | — | — | US | disclosed |
| WO-2022234864-A1 | METHOD FOR PRODUCING CYCLIC COMPOUND CONTAINING N-SUBSTITUTED AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4086272-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411462-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | HPGD 1470/4885CTSK 3284/4885ITGB3 4867/4885 |
| US-12312379-B2 | Methods for producing cyclic compounds comprising N-substituted amino acid residues | NGLY1, NPPA, VIP | HPGD 1470/4885CTSK 3284/4885ITGB3 4867/4885 |
| US-20240024245-A1 | MEDICINE PRODUCTION METHOD INCLUDING STEP OF FREEZE-DRYING WITH MIXED SOLVENT | NEFM, CMA1, CYP2W1 | HPGD 887/4885CTSK 1090/4885ITGB3 4747/4885 |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | HPGD 1470/4885CTSK 3284/4885ITGB3 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.